Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 9, 2026

74% of the $317 Billion Portfolio Warren Buffett Left for Berkshire Hathaway's New CEO, Greg Abel, Is Invested in These 8 Unstoppable Stocks in 2026

View original at nasdaq.com
74% of the $317 Billion Portfolio Warren Buffett Left for Berkshire Hathaway's New CEO, Greg Abel, Is Invested in These 8 Unstoppable Stocks in 2026 Key Points Warren Buffett has officially retired from the CEO role at Berkshire Hathaway…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The Motley Fool analyst team identified 10 best stocks to buy now, and Apple wasn't one of them

    80% confidence

  • Greg Abel has vowed to run Berkshire Hathaway similarly to his predecessor, as a long-term-minded, value-focused investor

    80% confidence

  • Chevron forecasts $10 billion to $20 billion in annual share buybacks through 2030

    80% confidence

  • Lower interest rates are expected to weigh on Bank of America's net interest income in the coming quarters

    80% confidence

Data points we hold from this source

Apple Podcasts · portfolio percentage20.1 percent
Apple Podcasts · shares retired44 percent
Apple Podcasts · buyback spending816 billion_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
74% of the $317 Billion Portfolio Warren Buffett Left for Berkshire Hathaway's New CEO, Greg Abel, Is Invested in These 8 Unstoppable Stocks in 2026 — Source | Via News | ViaNews EU